MX2009011512A - Nuevos compuestos peptidos ciclicos. - Google Patents

Nuevos compuestos peptidos ciclicos.

Info

Publication number
MX2009011512A
MX2009011512A MX2009011512A MX2009011512A MX2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A
Authority
MX
Mexico
Prior art keywords
cyclic peptide
new cyclic
hepatitis
peptide compounds
virus
Prior art date
Application number
MX2009011512A
Other languages
English (en)
Inventor
Takuya Makino
Toshio Yamanaka
Hidenori Ohki
Junya Ishida
Ayako Toda
Yu Harayama
Shingeki Kunikawa
Hiroaki Mizuno
Hiroaki Ohtake
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007902312A external-priority patent/AU2007902312A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2009011512A publication Critical patent/MX2009011512A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto péptido cíclico o una sal de él, que tiene actividades contra el virus de la hepatitis C basadas en la actividad inhibidora contra la replicación de ARN del replicón del virus de la hepatitis C, a un proceso para su preparación, a una composición farmacéutica que lo contiene, y a un método para el tratamiento profiláctico y/o terapéutico de la hepatitis C en un ser humano o en un animal.
MX2009011512A 2007-05-02 2008-04-25 Nuevos compuestos peptidos ciclicos. MX2009011512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007902312A AU2007902312A0 (en) 2007-05-02 New Cyclic Peptide Compounds
PCT/JP2008/058456 WO2008139986A1 (en) 2007-05-02 2008-04-25 New cyclic peptide compounds

Publications (1)

Publication Number Publication Date
MX2009011512A true MX2009011512A (es) 2009-11-12

Family

ID=39671779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011512A MX2009011512A (es) 2007-05-02 2008-04-25 Nuevos compuestos peptidos ciclicos.

Country Status (14)

Country Link
US (1) US8603975B2 (es)
EP (2) EP2455098A1 (es)
JP (1) JP5459545B2 (es)
KR (1) KR20100017547A (es)
CN (1) CN101687012A (es)
AU (1) AU2008250254B2 (es)
BR (1) BRPI0810203A2 (es)
CA (1) CA2684557A1 (es)
ES (1) ES2396170T3 (es)
IL (1) IL201485A0 (es)
MX (1) MX2009011512A (es)
RU (1) RU2436795C2 (es)
TW (1) TW200911839A (es)
WO (1) WO2008139986A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003259A (es) * 2008-09-24 2011-04-21 Astellas Pharma Inc Compuesto de peptido y metodo para producir el mismo.
EP2391376A4 (en) * 2009-01-30 2012-08-01 Enanta Pharm Inc ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
CN105579046A (zh) 2013-08-26 2016-05-11 英安塔制药有限公司 用于预防或治疗丙型肝炎的环孢菌素类似物
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
CN112661808B (zh) * 2020-12-23 2022-05-27 浙江大学 一种酯肽类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271267A (ja) 1991-04-23 1993-10-19 Fujisawa Pharmaceut Co Ltd Ｆｒ９０１４５９物質、その製法及び用途
ATE312843T1 (de) * 1998-07-01 2005-12-15 Debiopharm Sa Neues cyclosporin mit verbesserter wirkung
WO2002032447A2 (en) 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007015926A (ja) * 2003-10-06 2007-01-25 Fujisawa Pharmaceut Co Ltd Ｃ型肝炎治療剤
CA2583494C (en) 2004-10-01 2014-01-21 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
ES2357587T3 (es) 2004-10-01 2011-04-27 Debiopharm S.A. Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c.
WO2006054801A1 (en) * 2004-11-22 2006-05-26 Astellas Pharma Inc. New cyclic peptide compound
EP1957518B1 (en) 2005-10-26 2015-12-09 Astellas Pharma Inc. New cyclic peptide compounds

Also Published As

Publication number Publication date
US20100120672A1 (en) 2010-05-13
IL201485A0 (en) 2010-05-31
EP2455098A1 (en) 2012-05-23
TW200911839A (en) 2009-03-16
EP2150269A1 (en) 2010-02-10
AU2008250254A1 (en) 2008-11-20
EP2150269B1 (en) 2012-11-21
AU2008250254B2 (en) 2012-08-16
CA2684557A1 (en) 2008-11-20
KR20100017547A (ko) 2010-02-16
RU2009144538A (ru) 2011-06-10
CN101687012A (zh) 2010-03-31
RU2436795C2 (ru) 2011-12-20
WO2008139986A1 (en) 2008-11-20
BRPI0810203A2 (pt) 2014-10-14
ES2396170T3 (es) 2013-02-19
JP5459545B2 (ja) 2014-04-02
JP2010526024A (ja) 2010-07-29
US8603975B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
MX2009011512A (es) Nuevos compuestos peptidos ciclicos.
TW200732351A (en) New cyclic peptide compounds
MY202109A (en) Viral replication inhibitors
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
IL196815A0 (en) Hepatitis c virus inhibitors
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
HK1123733A1 (en) Viral hepatitis treatment
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
TW200606162A (en) Pyrazolopyridine derivatives
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MY194294A (en) Novel viral replication inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
BR112013028679A2 (pt) inibidores do vírus da hepatite c
WO2008069917A3 (en) Novel cyclic peptides
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
TW200612922A (en) Inhibitors of hsp90
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal